Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

  • End date
    May 6, 2022
  • participants needed
  • sponsor
    Rigel Pharmaceuticals
Updated on 6 December 2021
respiratory failure
diagnostic procedures


The study is a double-blind, randomized, placebo-controlled, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.


The primary objective of this study is:

To evaluate the efficacy of fostamatinib when used in combination with standard of care (SOC) in subjects hospitalized with COVID-19 without respiratory failure and with certain high risk prognostic factors, as measured by the change in clinical status score.

Condition SARS coronavirus, Severe Acute Respiratory Syndrome, Lung Disease, severe acute respiratory syndrome (sars), Viral pneumonia, pneumonitis, SARS Pneumonia, sars, COVID19, lung inflammation, Throat and Tonsil Infections, Pulmonary Disease, Pneumonia (Pediatric), SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Upper respiratory infection, pneumoniae, Pneumonia
Treatment Placebo, fostamatinib
Clinical Study IdentifierNCT04629703
SponsorRigel Pharmaceuticals
Last Modified on6 December 2021


Yes No Not Sure

Inclusion Criteria

years of age at screening
The subject or a legally authorized representative has provided written informed consent
Hospitalized COVID-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal prongs
Male or non-pregnant, non-lactating female subjects with SARS-CoV-2 infection documented by a hospital approved diagnostic test (eg, a Food and Drug Administration authorized test in the US) within 7 days prior to randomization

Exclusion Criteria

Pregnant or lactating female of childbearing potential
Use of extracorporeal membrane oxygenation (ECMO)
Uncontrolled hypertension (systolic blood pressure [BP] 160 mmHg and/or diastolic BP 100 mmHg), unstable angina, congestive heart failure of New York Heart Association classification III or IV, serious cardiac arrhythmia requiring treatment at screening
History of myocardial infarction within 1 month prior to screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note